DNA Sequencing Identifies Mitochondrial Mutations in Glaucoma Patients
By LabMedica International staff writers Posted on 26 Nov 2014 |
Diagnosis of glaucoma may be simplified by the development of a gene sequencing technique that detects mutations in the mitochondrial DNA of glaucoma patients.
Primary open-angle glaucoma occurs when optic nerve damage results in a progressive loss of the visual field. This is associated with increased pressure in the eye, which is caused by trabecular blockage. Since the microscopic passageways are blocked, the pressure builds up in the eye and causes imperceptible very gradual vision loss. Peripheral vision is affected first, but, if not treated, vision will eventually be lost entirely. Previous studies have produced evidence suggesting that glaucoma is linked to mitochondrial dysfunction.
Investigators at the University of Liverpool (United Kingdom) sought to confirm that mutations in mitochondrial DNA played a role in high-pressure primary open-angle glaucoma by analyzing new data from massively parallel sequencing of mitochondrial DNA.
To this end they recruited glaucoma patients with high-tension primary open-angle glaucoma together with ethnically matched and age-matched control subjects. The entire human mitochondrial genome was amplified in two overlapping fragments by long-range polymerase chain reaction (PCR) and used as a template for massively parallel sequencing on an Ion Torrent Personal Genome Machine (Life Technologies; Carlsbad, CA, USA). Life Technologies is a subsidiary of Thermo Fisher Scientific (Waltham, Massachusetts, USA).
Results revealed that in 16 of 32 patients with primary open-angle glaucoma, there were 22 mitochondrial DNA mutations consisting of seven novel mutations and eight previously reported disease-associated sequence variants. Eight of 22 (36.4%) of the mitochondrial DNA mutations were in complex I mitochondrial genes.
Senior author Dr. Colin Willoughby, professor of aging and chronic disease at the University of Liverpool, said, “Understanding the genetic basis of glaucoma can direct care by helping to determine the patient’s clinical risk of disease progression and visual loss. Increasing evidence suggests that mitochondrial dysfunction results in glaucoma and drugs that target mitochondria may emerge as future therapeutic interventions. Further studies on larger glaucoma numbers of patients are required to firmly establish the link between genetic defects in the mitochondrial genome and glaucoma development. Our research, however, has demonstrated that massively parallel sequencing is a cost-effective approach to detect a wide spectrum of mitochondrial mutations and will improve our ability to understand glaucoma, identify patients at risk of the disease or visual loss and support the development of new treatments.”
The study was published in the September 18, 2014, online edition of the journal Genetics Medicine.
Related Links:
University of Liverpool
Life Technologies
Thermo Fisher Scientific
Primary open-angle glaucoma occurs when optic nerve damage results in a progressive loss of the visual field. This is associated with increased pressure in the eye, which is caused by trabecular blockage. Since the microscopic passageways are blocked, the pressure builds up in the eye and causes imperceptible very gradual vision loss. Peripheral vision is affected first, but, if not treated, vision will eventually be lost entirely. Previous studies have produced evidence suggesting that glaucoma is linked to mitochondrial dysfunction.
Investigators at the University of Liverpool (United Kingdom) sought to confirm that mutations in mitochondrial DNA played a role in high-pressure primary open-angle glaucoma by analyzing new data from massively parallel sequencing of mitochondrial DNA.
To this end they recruited glaucoma patients with high-tension primary open-angle glaucoma together with ethnically matched and age-matched control subjects. The entire human mitochondrial genome was amplified in two overlapping fragments by long-range polymerase chain reaction (PCR) and used as a template for massively parallel sequencing on an Ion Torrent Personal Genome Machine (Life Technologies; Carlsbad, CA, USA). Life Technologies is a subsidiary of Thermo Fisher Scientific (Waltham, Massachusetts, USA).
Results revealed that in 16 of 32 patients with primary open-angle glaucoma, there were 22 mitochondrial DNA mutations consisting of seven novel mutations and eight previously reported disease-associated sequence variants. Eight of 22 (36.4%) of the mitochondrial DNA mutations were in complex I mitochondrial genes.
Senior author Dr. Colin Willoughby, professor of aging and chronic disease at the University of Liverpool, said, “Understanding the genetic basis of glaucoma can direct care by helping to determine the patient’s clinical risk of disease progression and visual loss. Increasing evidence suggests that mitochondrial dysfunction results in glaucoma and drugs that target mitochondria may emerge as future therapeutic interventions. Further studies on larger glaucoma numbers of patients are required to firmly establish the link between genetic defects in the mitochondrial genome and glaucoma development. Our research, however, has demonstrated that massively parallel sequencing is a cost-effective approach to detect a wide spectrum of mitochondrial mutations and will improve our ability to understand glaucoma, identify patients at risk of the disease or visual loss and support the development of new treatments.”
The study was published in the September 18, 2014, online edition of the journal Genetics Medicine.
Related Links:
University of Liverpool
Life Technologies
Thermo Fisher Scientific
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans